Clinical trial
Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly…
NCT00304031 · Radiation Therapy Oncology Group, Other · Completed
Key facts
| NCT number | NCT00304031 |
|---|---|
| Title | Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma |
| Official title | Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma |
| Lead sponsor | Radiation Therapy Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH European Organisation for Research and Treatment of Cancer - EORTC NRG Oncology |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug, Radiation |
| Interventions | Concurrent temozolomide, Concurrent radiation therapy, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle |
| Enrollment | 1,173 |
| Start date | Jan 1, 2006 |
| Primary completion | Feb 1, 2011 |
| Completion | Dec 1, 2016 |
| First posted | Mar 17, 2006 |
| Last update posted | Jun 9, 2020 |
| Countries | Canada, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: